
In this episode, JD Denham and Will Haas discuss GLP peptides with Jay Campbell, exploring their effects on fat loss and performance, as well as the current market dynamics and regulations.
Medical Disclaimer: We are not doctors. The content in this video is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Any compounds discussed may be intended for research purposes only. Use at your own risk. Welcome back, warriors! In this episode of Peptide of the Week, JD Denham and William T. Haas sit down with Jay Campbell to break down the truth about GLP peptides, what’s really happening behind the scenes, and where the future of fat loss and performance is heading. From semaglutide to retatrutide and beyond this episode cuts through the noise and gives you real insight into how these compounds actually work and how most people are using them wrong. Chapters: 00:00 – Intro & Jay Campbell Joins 03:33 – Peptide Sciences Shutdown Explained 08:10 – Big Pharma Pressure & Market Control 14:34 – GLP-1 Monopoly, FDA & Market Shift 18:39 – Fake Peptides & Bad Actors 23:20 – New Regulations & Testing Standards 27:21 – Compounding Pharmacies Under Attack 33:33 – MedV, AI Doctors & Affiliate Risk 39:33 – What’s Coming Next in Peptides 45:22 – FLGR-242 & Clotho Breakdown 55:35 – Nootropics…
Hosts: JD Denham, Will Haas
Guest: Jay Campbell
Organizations: Big Pharma, FDA, MedV, AI Doctors, Compounding Pharmacies
Products: semaglutide, retatrutide, FLGR-242, Nootropics, Cognitive Peptides
Explore listener stats, chart rankings, contacts and more on the Peptide of The Week podcast page.